Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path UnclearNEW YORK – Testing for somatic copy number alterations at a specific locus on chromosome 9 in squamous head and neck cancer cells may identify the patients most likely to benefit from immune checkpoint inhibitors, according to a new study published… Nov 16 22November 16, 2022Article at GenomeWeb
Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC PatientsPARIS – In a series of presentations at the European Society for Medical Oncology Congress on Sunday, researchers demonstrated how repeatedly testing advanced non-small cell lung cancer patients for biomarkers can inform treatment strategies for… Sep 11 22September 11, 2022Article at GenomeWeb
Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast CancerNEW YORK – Agendia is getting closer to commercially launching a 53-gene signature, dubbed ImPrint, to help guide immunotherapy treatment for early-stage breast cancer patients. The company's commercialization plans for the test, currently available… Jun 21 22June 21, 2022Article at GenomeWeb
Intermountain Healthcare Rolling Out Galleri Multi-Cancer Early Detection Test in Pilot ProgramNEW YORK – As of Monday, Intermountain Healthcare employees over age 50 are eligible for cancer screening with Grail's blood-based early detection assay as a covered benefit. The multi-cancer early detection test, dubbed Galleri, is designed to pick… May 15 22May 15, 2022Article at GenomeWeb
New Epigenomic Biomarker Could Predict CAR T-Cell Therapy Resistance in Advanced Childhood LeukemiaNEW ORLEANS – Children with acute lymphoblastic leukemia (ALL) whose cells express an epigenomic biomarker rooted in DNA methylation patterns may be less likely to respond to CD19-directed CAR T-cell therapy, according to research presented at the… Apr 12 22April 12, 2022Article at GenomeWeb
Pangea Biomed Builds on RNA-Based Drug Matching to Expand Precision Oncology OpportunitiesNEW YORK – Pangea Biomed on Thursday said it would use $7 million in seed funding to use its transcriptomics-based ENLIGHT platform to get more cancer patients on precision oncology treatments. Tel Aviv, Israel-based Pangea's Expression Networks for… Apr 06 22April 06, 2022Article at GenomeWeb
ESMO Oncologists Debate Optimal Timing for Broad NGS, Align on Key Barriers to Precision OncologyNEW YORK – In an interactive session during the European Society for Medical Oncology (ESMO) Congress on Tuesday, oncologists debated whether performing comprehensive molecular profiling on a patient's cancer as early as possible following diagnosis… Sep 22 21September 22, 2021Article at GenomeWeb
Oncocyte Launches Prospective Registry to Drive DetermaRx Adoption, Improve CoverageNEW YORK – With the launch of a new nationwide real-world evidence registry, Oncocyte wants to bolster validation data supporting the use of its 14-gene expression assay, DetermaRx, as a predictive tool for guiding adjuvant treatment in early-stage… Aug 26 21August 26, 2021Article at GenomeWeb
Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing DiscussionNEW YORK – The results of the Phase III OlympiA trial, presented during the American Society of Clinical Oncology's virtual annual meeting, has the oncology community asking: should germline genetic testing for mutations in BRCA1 and BRCA2 be offered… Jun 06 21June 06, 2021Article at GenomeWeb
MSK Study Underscores Need to Validate Cancer-Specific Tumor Mutational Burden Cutoffs NEW YORK – Applying a universal cutoff for high tumor mutational burden (TMB) across tumor types may not capture all cancer patients who will respond well to immunotherapy, according to an analysis published today in JAMA Oncology. … Feb 16 21February 16, 2021Article at GenomeWeb
Researchers ID Four Small Cell Lung Cancer Subtypes, Suggest Future Treatment Implications NEW YORK – Patients with small cell lung cancer could soon benefit from a more personalized approach to treatment than they have seen in years past, thanks to a group of researchers who have defined four subtypes of the disease, each… Jan 25 21January 25, 2021Article at GenomeWeb
Agendia FLEX Registry Powers Genomics Research on Underrepresented Breast Cancer Patients NEW YORK – Agendia has amassed tumor samples, as well as genomic and clinical data, from 6,000 breast cancer patients it has tested within the FLEX Registry, a resource that the molecular diagnostics firm is hoping will be a rich… Dec 21 20December 21, 2020Article at GenomeWeb
MSK Researchers Find High Prevalence of Germline Mutations in Patients With Early-Onset Cancers NEW YORK – A significant portion of young adults with early-onset cancers may harbor germline mutations, suggesting the need for universal germline testing in this population, according to new data presented during the second virtual session… Jun 20 20June 20, 2020Article at GenomeWeb
Tumor Mutational Burden in Blood May Predict Immunotherapy Response in Head, Neck CancerNEW YORK – An analysis of retrospective data from the Phase III EAGLE study suggests that tumor mutational burden (TMB), as assessed through cell-free DNA in patients' blood plasma, may predict which head and neck squamous cell carcinoma patients are… Jun 04 20June 04, 2020Article at GenomeWeb
